VIDEO: Advances in prognostic indicators for AML may help guide treatment

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

There are many. There are some that are in standard use and will still remain in standard use, such as karyotype, and this is just looking at chromosomes and understanding what are the added or missing chromosomes, and if there are two chromosomes attached to each other, this is a very powerful indicator of prognosis of outcomes in acute myeloid leukemia.

And if you add to that, the mutations where some have prognostic implications, such as mutations in p53, which lead to adverse outcomes, we are able to better stratify patients between categories, which are good, intermediate, and adverse. And then there are next-generation tools that would allow us to understand better prognosis and hopefully, inform us on treatment decisions. Measurement of MRD methods would be the most important ones.

There are various ways of doing that, and maybe in the future, gene expression patterns or expression on cell markers that would allow us to understand better responses to specific therapies.